Tempest Therapeutics, Inc.
Clinical-stage oncology company developing oral small molecule therapeutics to treat cancer.
TPST | US
Overview
Corporate Details
- ISIN(s):
- US69014Q1013 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 2000 SIERRA POINT PARKWAY, 94005 BRISBANE
- Website:
- https://www.tempesttx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Tempest Therapeutics, Inc. is a clinical-stage oncology company focused on developing a diverse portfolio of small molecule product candidates. The company develops first-in-class oral therapeutics that utilize both targeted and immune-mediated mechanisms to treat cancer. By exploring novel and validated biological pathways, Tempest aims to create innovative treatments with broad potential benefits for cancer patients. Its lead product candidate is amezalpat (TPST-1120), which is being evaluated in clinical trials for various forms of cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Tempest Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Tempest Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Tempest Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
